Sun Pharmaceutical Industries Ltd share price logo

Sun Pharmaceutical Industries Ltd Share Price

(SUNPHARMA)

₹1787.40.91%

as on 04:01PM, 25 Apr 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Sun Pharma Performance

  • Day's Low

    Day's High

    ₹1,764.2
    Day's Price Range
    ₹1,815.5
  • 52 Week's Low

    52 Week's High

    ₹1,377.2
    52-Week Price Range
    ₹1,960.35
1 Month Return+ 1.62 %
3 Month Return+ 0.03 %
1 Year Return+ 18.64 %
Previous Close₹1,803.90
Open₹1,806.00
Volume20.37L
Upper Circuit₹1,984.20
Lower Circuit₹1,623.60
Market Cap₹4,28,857.13Cr

Sun Pharma Fundamentals

P/E Ratio

37.47

PEG Ratio

3.54

Market Cap

₹4,28,857.13 Cr

P/B Ratio

16.41

EPS

40.21

Dividend Yield

0.83

Sector

Pharmaceuticals

ROE

12.05

Sun Pharma Analyst Rating

based on 37 analysts

BUY

81.08%

Buy

10.81%

Hold

8.11%

Sell

Based on 37 analysts offering long term price targets for Sun Pharma. An average target of ₹2047.89

Source: S&P Global Market Intelligence

Sun Pharma Share analysis

Sun Pharma price forecast by 37 analysts

Upside of14.57%

High

₹2450

Target

₹2047.89

Low

₹1500

Sun Pharma target price ₹2047.89, a slight upside of 14.57% compared to current price of ₹1787.4. According to 37 analysts rating.

Source: S&P Global Market Intelligence

Key events for Sun Pharmaceutical Industries Ltd

  • Sun Pharma Reports Positive Osteoarthritis Drug Trial Results - 24 Apr, 2025

    Sun Pharmaceutical Industries and Moebius Medical announced positive results for MM-II, a novel osteoarthritis treatment, showing significant pain relief and a favorable safety profile. This development may provide a promising alternative to existing treatments.
  • Sun Pharma Anticipates Strong US Market Growth - 23 Apr, 2025

    Sun Pharmaceutical Industries is projected to deliver a 12% year-over-year growth in the US market, primarily due to the success of its specialty portfolio.
  • Sun Pharma Shares Rise with Buy Recommendation - 20 Apr, 2025

    Sun Pharmaceutical Industries Ltd shares closed at Rs.1,757.00, up 3.77%. Emkay Global recommends a Buy with a target price of Rs.2,400, suggesting a 40% upside.
  • Sun Pharma Faces Recall Amid Regulatory Challenges - 14 Apr, 2025

    Sun Pharmaceutical Industries is recalling several medicines from the US market due to manufacturing-related problems, contributing to a challenging environment for the company amid strong competition and regulatory pressures.
  • Sun Pharma Faces Recall Amid Stock Recovery - 13 Apr, 2025

    Sun Pharmaceutical Industries has seen a recovery in its stock, regaining nearly half of its earlier losses. However, it is also recalling 13,700 bottles of Gabapentin capsules due to cross-contamination concerns, which may impact investor sentiment.
  • Sun Pharma Gains Court Approval for Leqselvi Launch - 10 Apr, 2025

    Sun Pharmaceutical Industries received a favorable ruling from the U.S. Court of Appeals, lifting the injunction on Leqselvi's launch, projected to boost sales significantly in FY26 and FY27.
  • Sun Pharma Faces Challenges from US Tariff Announcement - 09 Apr, 2025

    Sun Pharmaceutical Industries Ltd is expected to face challenges due to upcoming US tariffs on pharmaceutical imports, leading to a negative trading outlook and lower stock performance.
  • Sun Pharma Launches New Drug Amid Market Challenges - 07 Apr, 2025

    Sun Pharmaceutical Industries launched FEXUCLUE for Erosive Esophagitis, demonstrating high efficacy in trials. However, shares fell 3.47% as the Nifty Pharma index hit a 10-month low.
  • Sun Pharma Faces Tariff Concerns Amid Growth Prospects - 04 Apr, 2025

    Sun Pharma shares declined due to tariff concerns after Trump's announcement, but the company is projected to achieve significant sales growth in Q4FY25, maintaining a positive outlook from analysts.
  • Sun Pharma Shares Surge on Tariff Exemption News - 03 Apr, 2025

    On April 3, 2025, Sun Pharmaceutical Industries saw its shares rise over 5% after the U.S. confirmed that Indian pharmaceutical exports would not face new tariffs. This decision is viewed positively by brokerages, highlighting Sun Pharma's resilience amid potential tariff disruptions.
  • Sun Pharma Reports Strong Growth Amid Challenges - 02 Apr, 2025

    Sun Pharmaceutical Industries Ltd reported a 10.4% revenue growth in FY24, driven by specialty drugs and a robust Indian market, despite potential tariff pressures on exports.
  • Concerns Over Tariffs Impacting Pharma Sector - 30 Mar, 2025

    India's 10% tariff on US pharma imports raises concerns among industry groups, highlighting potential cost burdens for distributors and generic manufacturers amid minimal US duties.
  • Sun Pharma Enters Merger Agreement with Checkpoint Therapeutics - 29 Mar, 2025

    Sun Pharmaceutical Industries Ltd has entered into a merger agreement with Checkpoint Therapeutics, Inc. This merger aims to facilitate the launch of UNLOXCYT in the U.S. and support marketing authorization in Europe, enhancing the company's strategic position in the oncology market.
  • Sun Pharma Faces Challenges Amid Market Decline - 27 Mar, 2025

    Sun Pharmaceutical Industries Ltd is impacted by Lyndra Therapeutics ceasing operations due to funding issues and a broader decline in Indian pharma stocks amid tariff concerns.

Insights on Sun Pharmaceutical Industries Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 12.11% to 12.24% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, SUNPHARMA stock has moved up by 2.4%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 12.58K Cr → 14.14K Cr (in ₹), with an average increase of 3.8% per quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 8.89% to 8.92% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 18.02% to 18.05% in Dec 2024 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 54.48% of holdings in Dec 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 49.7% return, outperforming this stock by 31.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 136.8% return, outperforming this stock by 42.1%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 3.04K Cr → 2.90K Cr (in ₹), with an average decrease of 4.5% per quarter

Sun Pharma News

Top Gainers and Losers in Indian Markets on April 25

ACC plunged over 6% after its Q4 earnings missed Street expectations, reflecting tepid demand recovery in the cement sector. Margin pressures due to rising fuel and raw material costs added to the negative surprise. The stock remained under selling pressure as analysts trimmed earnings estimates post results.25 Apr, 2025 04:32 PM

Q4 Results impact: ACC, Cyient shares tumble 6% amid tepid March quarter earnings

The Adani Group firm on April 24 reported a consolidated net profit of Rs 751 crore for Q4 FY25. This marked a fall of nearly 20 percent from the Rs 943 crore net profit reported in Q4 FY24. The firms consolidated revenue however rose 13 percent year-on-year to Rs 5,992 crore in Q4FY25 as against Rs 5,317 crore in Q4FY24. The cement company also declared dividend of Rs 7.5 per share for FY25. June 13 has been fixed as the record date for the dividend and it shall be paid before July 1. The shares of the company have now recorded their worst fall in 2025 so far. Axis Capital has cut the rating of ACC shares to Reduce from Add, with a target price of Rs 2,050 apiece. The latest target price, however, implies an upside potential of nearly 6 percent from the current market price.25 Apr, 2025 02:13 PM

ACC Faces Major Loss After Q4 Results Decline

Shares of Adani Group-owned cement manufacturer tumbled over 6 per cent on Friday after its profit for the fourth quarter of the financial year 2025 (Q4 FY25) declined 20.4 per cent year-on-year (Y-o-Y). ACC's stock fell as much as 6.5 per cent during the day to ₹1,931 per share, the worst intraday loss since November 21 this year, according to Bloomberg data. The stock trimmed losses to trade 5 per cent lower at ₹1,961 apiece, compared to a 1.38 per cent decline in Nifty50 as of 12:11 PM. The company's net profit for the fourth quarter declined 20.4 per cent Y-o-Y to ₹7,51.03 crore. The Adani-owned company's revenue from operations grew 12.7 per cent to ₹5,991.67 crore amid higher trade sales volume and share of premium products in trade sales. Revenue growth surpassed Bloomberg analysts estimate of ₹5,904 crore. The company's total expenses in Q4 FY25 stood at ₹5,514.82 crore, up 13.11 per cent Y-o-Y. Earnings before interest, taxes, depreciation, and amortisation (Ebitda) stood at ₹830 crore, down 0.84 per cent. Ebitda margin declined to 13.7 per cent in Q4 FY25 from 15.5 per cent the year before. Additionally, ACC announced a dividend on equity shares at ₹7.50 per share.25 Apr, 2025 12:36 PM
View More

Sun Pharma Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹12,156.86Cr (-)₹11,813.33Cr (↓2.83%)₹12,524.51Cr (↑6.02%)₹13,264.22Cr (↑5.91%)₹13,436.94Cr (↑1.30%)
Net Income₹2,568.03Cr (-)₹2,666.59Cr (↑3.84%)₹2,871.25Cr (↑7.67%)₹3,030.67Cr (↑5.55%)₹2,917.54Cr (↓3.73%)
Net Profit Margin21.12% (-)22.57% (↑6.87%)22.93% (↑1.60%)22.85% (↓0.35%)21.71% (↓4.99%)
Value in ₹ crore
Details2021202220232024
Total Assets₹44,366.74Cr (-)₹41,830.91Cr (↓5.72%)₹41,937.94Cr (↑0.26%)₹41,896.83Cr (↓0.10%)
Total Liabilities₹17,428.27Cr (-)₹17,242.96Cr (↓1.06%)₹18,189.58Cr (↑5.49%)₹18,202.43Cr (↑0.07%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹1,305.85Cr (-)-₹416.51Cr (↓131.90%)₹7,636.36Cr (↓1,933.42%)₹507.08Cr (↓93.36%)-₹292.42Cr (↓157.67%)

Sun Pharma Index Inclusions

S&P BSE SENSEX 50

₹25,083.83

-0.85 (-215.82%)

S&P BSE 100 ESG

₹402.54

-0.98 (-3.97%)

Nifty Healthcare

₹13,829.80

-2.42 (-343.55%)

S&P BSE 250 LargeMidCap

₹10,255.35

-1.4 (-145.86%)

BSE 100

₹25,114.27

-1.18 (-299.88%)

Nifty LargeMidcap 250

₹15,205.20

-1.81 (-279.8%)

Nifty100 Eq Weig

₹30,988.50

-1.9 (-601.05%)

Nifty 200

₹13,296.85

-1.36 (-183.35%)

S&P BSE Low Volatility

₹1,762.22

-0.93 (-16.5%)

S&P BSE Dividend Stability

₹963.55

-1.79 (-17.54%)

NIFTY 50

₹24,039.35

-0.86 (-207.35%)

BSE 500

₹34,359.02

-1.5 (-521.65%)

BSE Healthcare

₹41,884.76

-2.43 (-1044.99%)

BSE 200

₹10,845.22

-1.35 (-148.33%)

Nifty100 Low Volatility 30

₹19,299.00

-0.78 (-151.5%)

NIFTY 100

₹24,581.30

-1.12 (-279.6%)

S&P BSE 100 LargeCap TMC

₹8,862.82

-1.14 (-101.82%)

NIFTY PHARMA

₹21,482.55

-2.24 (-492.05%)

BSE MFG

₹981.86

-1.08 (-10.77%)

S&P BSE Momentum

₹2,022.55

-2.4 (-49.7%)

S&P BSE Largecap

₹9,238.48

-1.18 (-110.53%)

SENSEX

₹79,212.53

-0.74 (-588.9%)

Nifty 500

₹21,848.15

-1.5 (-332.5%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

Sun Pharma Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
54.48%
0.00
Foreign Institutions
18.05%
0.17
Mutual Funds
12.24%
1.02
Retail Investors
8.92%
0.33
Others
6.31%
-2.81

Sun Pharma Key Indicators

Details20202021202220232024
Return On Equity %13.63.53-5.1913.8912.05
Details20202021202220232024
Return On Assets %9.666.557.8220.2122.86
Details20202021202220232024
Book Value Per Share (₹)188.66193.65200.11233.38265.36
Details20202021202220232024
Earning Per Share (₹)17.459.5214.235.6840.21

Sun Pharma Valuation

Sun Pharma in the last 5 years

  • Overview

  • Trends

Lowest (19.47x)

March 23, 2020

Today (37.47x)

April 25, 2025

Industry (55.10x)

April 25, 2025

Highest (184.63x)

August 28, 2020

LowHigh

Sun Pharma Earnings and Dividends

  • Sun Pharmaceutical Industries Ltd Earnings Results

    Sun Pharmaceutical Industries Ltd’s net profit jumped 15.04% since last year same period to ₹2,903.38Cr in the Q3 2024-2025. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated -4.5% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Sun Pharmaceutical Industries Ltd Dividends January,2025

    In the quarter ending December 2024, Sun Pharmaceutical Industries Ltd has declared dividend of ₹10.50 - translating a dividend yield of 1.34%.

    Read More about Dividends

Sun Pharma Technicals Summary

Bearish

Neutral

Bullish

Bullish

Sun Pharmaceutical Industries Ltd is currently in a Bullish trading position according to technical analysis indicators.

Sun Pharma Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹4,28,857.13 Cr52.97%0.68₹9,648 Cr₹48,496 Cr
HOLD₹1,59,612.98 Cr29.57%0.50₹1,600 Cr₹7,845 Cr
BUY₹1,09,614.17 Cr31.63%0.67₹1,656 Cr₹10,727 Cr
BUY₹37,440.71 Cr-2.83%0.58₹1,297 Cr₹14,755 Cr
HOLD₹23,855.08 Cr-4.09%0.50₹772 Cr₹5,664 Cr

About Sun Pharma

Sun Pharmaceutical Industries Ltd., incorporated in 1983, is a global specialty generic pharmaceuticals company with a presence in over 150 countries. The company is headquartered in Mumbai, India, and has operations in three primary lines of business: branded formulations, specialty generics, and active pharmaceutical ingredients (API).

Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.

Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.

Revenue: ₹13,436.94Cr as on December 2024 (Q4 24)
Net Profit: ₹2,917.54Cr as on December 2024 (Q4 24)
Listing date: 08 Feb, 1995
Revital Share Price
Volini Share Price
Abzorb Share Price
Pepfiz Share Price
OrganisationSun Pharma
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Sun Pharmaceutical Industries Ltd

What is Sun Pharmaceutical Industries Ltd price today?

Sun Pharmaceutical Industries Ltd share price today stands at ₹1787.4, Open: ₹1806, Previous Close: ₹1803.9, High: ₹1815.5, Low: ₹1764.2, 52 Week High: ₹1960.35, 52 Week Low: ₹1377.2.

How to Buy Sun Pharmaceutical Industries Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Sun Pharmaceutical Industries Ltd shares

What are today's traded volumes of Sun Pharmaceutical Industries Ltd?

Today's traded volume of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is 20.37L.

What is today's market capitalisation of Sun Pharmaceutical Industries Ltd?

Today's market capitalisation of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is ₹428857.13Cr.

What is the 52 Week High and Low Range of Sun Pharmaceutical Industries Ltd?

Sun Pharmaceutical Industries Ltd (SUNPHARMA)
Price
52 Week High
₹1960.35
52 Week Low
₹1377.2

How much percentage Sun Pharmaceutical Industries Ltd is down from its 52 Week High?

Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1787.4. It is down -8.82% from its 52 Week High price of ₹1960.35

How much percentage Sun Pharmaceutical Industries Ltd is up from its 52 Week low?

Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1787.4. It is up 29.79% from its 52 Week Low price of ₹1377.2